Tenalisib is under clinical development by Rhizen Pharmaceuticals and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase II drugs for Marginal Zone B-cell Lymphoma have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tenalisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tenalisib overview

Tenalisib (RP-6530) is under development for the treatment of relapsed or refractory hematologic malignancies including relapsed and chronic lymphocytic leukemia, refractory  cutaneous T-Cell lymphoma, peripheral T-Cell lymphomas (PTCL), diffuse large B-cell lymphoma and Hodgkin Lymphoma, relapsed or refractory classical Hodgkin lymphoma, follicular lymphoma, marginal zone lymphoma, waldenstrom macroglobulinemia, small lymphocytic lymphoma, triple negative breast cancer, acute myelocytic leukemia, solid tumors and ovarian cancer and vitiligo. It is administered through oral route, topical and inhalational route. The drug candidate is a dual phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor and Salt-Inducible Kinase 3 (SIK3) inhibitor. It was also under development for asthma and chronic obstructive pulmonary disease (COPD), airway inflammation, arthritis and multiple myeloma.

Rhizen Pharmaceuticals overview

RhizenPharmaceuticals (RhizenPharma), a subsidiary of Alembic Pharmaceuticals Ltd, is a biopharmaceutical company that discovers and develops small molecule drugs. The company’s research products include c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 agonist. It conducts research in the therapeutic areas of oncology, immune inflammation and metabolic disorders such as diabetes and obesity. RhizenPharma’s products find application in the treatment of diseases such as solid tumors, B cell lymphomas, hematological malignancies, asthma, diabetes and chronic obstructive pulmonary disease, among others. It collaborates with other pharmaceutical companies. Rhizenis headquartered in La Chaux-de-Fonds, Switzerland.

For a complete picture of Tenalisib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.